Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Thyroid and Glucose and Energy Metabolism
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
N/A N=90 FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
Phase 2 N=13 Energy Metabolism in Thyroidectomized Patients
Thyroid Goiter · Hypothyroidism · Thyroid Cancer
Primary: Short Term Change in Weight — 1.7; -0.76 Kilogram
Phase 4 N=11 Hypothyroidism Treated With Calcitonin
Hypothyroidism
Primary: Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease — -36.33 score on a scale
Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Phase 1 N=12 ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
Graves Disease
Primary: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities up to Week 22 Compared to Baseline. — 311; 293; 18; 0…
Phase 2 N=7 Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
Phase 3 N=1,203 Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
Subclinical Hypothyroidism · Hypothyroxinemia · Pregnancy
Primary: Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or…
N/A N=14 Mechanistic Study of Subclinical Hypothyroidism In the Elderly
Subclinical Hypothyroidism
Primary: TSH Area Under the Curve — 267.8; 266.2 μIU*min/mL
N/A N=39 Glucocorticoids and Bone in Graves' Ophthalmopathy
Graves Ophthalmopathy
Primary: Percent Change Lumbar Spine Bone Mineral Density — 1.37 Percentage change
Phase 3 N=31 Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)
Healthy Volunteers
Primary: Energy Expenditure — 1.37; 1.40; 1.28; 1.27 kcal/min — p=0.0001
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Phase 2 N=22 Effects of Liothyronine on Energy Expenditure and Cardiovascular Function
Healthy
Primary: Cardiac Output — -3.7; -1.4; 1 millilitres
Phase 4 N=66 Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Hypothyroidism;Postablative
Primary: Thyroid Stimulating Hormone (TSH) — -0.676 mIU/L — p=<0.0001
N/A N=48 Thyroid Hormone Dose Adjustment in Pregnancy
Pregnancy · Hypothyroidism
Primary: Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation — 24; 21 participants
Phase 4 N=30 Preoperative Steroids in Autoimmune Thyroid Disease
Thyroid Diseases
Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale
N/A N=142 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
Phase 2 N=1,553 Studies of Elevated Parathyroid Activity
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants
Phase 4 N=36 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Graves Disease · Hyperthyroidism
Primary: Blood Loss During Surgery — 61.67; 161.67 mL
Phase 2 N=19 Radioactive Iodide Therapy for Pediatric Graves' Disease
Graves' Disease
Primary: Dosimetry Studies
N/A N=4 Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Phase 3 N=70 Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery
Cardiac Surgery Intensive Care Treatment · Delayed Recovery From Anaesthesia · Euthyroid Sick Syndrome
Primary: Change in Glasgow Coma Scale (GCS) From Intervention Initiation to ICU Discharge (Δ) — 6.65; 2.69 Score on a scale
N/A N=12 Treatment Trial of Subclinical Hypothyroidism in Down Syndrome
Down Syndrome · Subclinical Hypothyroidism
Primary: Change in Lipid Panel From Baseline at 6, 12 and 18 Months. — 160; 170; 163; 172 mg/dL
Phase 3 N=11 Liothyronine (T3) for Bipolar Depression
Depression · Bipolar Disorder
Primary: Hamilton Rating Scale for Depression Scores — 3.50; 7.25 units on a scale
Phase 2 N=46 Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Hypothyroidism
Primary: Dose Conversion Factor — 4.24 Ratio
Phase 2 N=63 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Thyroid Cancer
Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants
Phase 4 N=8 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Phase 2 N=34 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
Thyroid Cancer · Differentiated Thyroid Carcinoma
Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…
Phase 2 N=15 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
Graves' Disease
Primary: Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize After 12 Week Treatment — 0 percentage of participants